Drug-Drug Interaction Study of Qualaquin and Midazolam
Information source: Mutual Pharmaceutical Company, Inc.
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: Midazolam Alone (Drug); Qualaquin (quinine) alone steady state (Drug); Midazolam and Qualaquin at steady state (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Mutual Pharmaceutical Company, Inc. Official(s) and/or principal investigator(s): Matthew Davis, MD, Study Chair, Affiliation: Mutual Pharmaceutical Dennis Swearingen, MD, Principal Investigator, Affiliation: MDS Pharma Services
Summary
This is an open label non-randomized single sequence, single group two way drug interaction
study in healthy adult volunteers to determine the extent to which quinine, an inducer of
cytochrome p450 CYP 3A4, affects the pharmacokinetics of midazolam, an accepted probe drug
for CYP 3A4. The study will also determine the extent to which midazolam affects the
pharmacokinetics of quinine.
Clinical Details
Official title: A Pharmacokinetic Interaction Study Evaluating the Effect of Qualaquin (Quinine Sulfate) Capsules on Midazolam
Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Primary outcome: Maximum Serum Concentration (Cmax)Area Under the Concentration Time Curve From Zero to T (AUC 0-t) for Midazolam and 1-hydroxy Midazolam at Baseline and With Qualaquin (Quinine) at Steady State. Area Under the Concentration Time Curve From Zero to Infinity (AUC Inf) for Midazolam and 1 Hydroxy Midazolam Before (Day 1) and After (Day 10) Qualaquin (Quinine). The Area Under the the Concentration Time Curve From Zero to Tau (0-8hrs) for Qualaquin (Quinine) AUC Tau Before and After Midazolam
Detailed description:
This is an open label single sequence single group non-randomized two way drug interaction
study in healthy adult volunteers to determine the extent to which quinine, an inducer of
cytochrome p450 CYP 3A4, affects the pharmacokinetics of midazolam, an accepted probe drug
for CYP 3A4. The study will also determine the extent to which midazolam affects the
pharmacokinetics of quinine. This will compare the pharmacokinetics of midazolam and
quinine at baseline to their kinetics when they are taken together in 24 normal healthy
adult volunteers who will serve as their own controls. All patients will be confined to the
study site throughout the entire 11 day study period. On day 1 after a fast of at least
10 hours, all study participants will receive a single oral dose of midazolam 2 mg. Blood
will be drawn at times sufficient to adequately define the baseline concentration time curve
for midazolam and its metabolite, 1-hydroxy-midazolam. On the morning of day 4, after a 3
day washout period and following a fast of at least 10 hours, all volunteers will begin a
regimen of 324 mg of quinine sulfate by mouth every 8 hours. All subjects will continue
this regimen from day 4-10 (21 total doses). Blood will be drawn after the first daily dose
of quinine on days 4 and 9 at times sufficient to adequately define the baseline and steady
state concentration time curves for quinine. Additional blood will be drawn prior to the
first daily dose of quinine on days 7,8,9,and 10. On day 10 after a fast of at least a 10
hours, all participants will receive both midazolam 2 mg and quinine 324 mg together.
Blood will be drawn a times sufficient to characterize the pharmacokinetics of midazolam,
1-hydroxy-midazolam and quinine under the stated conditions.
Eligibility
Minimum age: 18 Years.
Maximum age: 45 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Medically healthy non-smoking, non-obese (≥ 60 kg males, ≥52 kg females within 15%
of IBW) adult volunteers 18-45 years of age
Exclusion Criteria:
- Subjects with history or presence of significant cardiovascular disease (including
hypotension, hypertension, bradycardia or EKG abnormalities), pulmonary, hepatic,
gallbladder or biliary tract, renal, hematologic, gastrointestinal, endocrine,
immunologic, dermatologic, neurologic, psychiatric disease or an active sexually
transmitted disease.
- Subjects with significant blood loss in the prior 56 days, plasma donation within 7
days , hemoglobin < 12. 0 g/dl or who have participated in another clinical trial
within the prior 30 days.
- Subjects with recent (2-year) history or evidence of alcoholism or drug abuse.
- Subjects who have used any drugs or substances known to inhibit or induce cytochrome
P450 (CYP) enzymes 10 days or 28 days respectively prior to the first dose and
throughout the study.
- Subjects who have received monoamine oxidase inhibitors or been on a special diet
within 28 days of starting the study.
- Subjects who test positive at screening for human immunodeficiency virus (HIV),
hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV).
Subjects who are pregnant or lactating, taking hormone replacement therapy or have known
allergies to quinine sulfate, mefloquine, quinidine or midazolam and other
benzodiazepines.
Locations and Contacts
MDS Pharma Services, Phoenix, Arizona 85044, United States
Additional Information
Recalls, Market Withdrawals and Safety Alerts Daily Med - Posting of Recently Submitted Labeling to the FDA
Starting date: March 2007
Last updated: August 22, 2012
|